Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
出版年份 2017 全文链接
标题
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time
作者
关键词
-
出版物
Nature Communications
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-08-30
DOI
10.1038/s41467-017-00451-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma
- (2017) Weiwei Zhai et al. Nature Communications
- A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
- (2016) Alejandra Bruna et al. CELL
- Precision oncology: origins, optimism, and potential
- (2016) Vinay Prasad et al. LANCET ONCOLOGY
- CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma
- (2016) Elisa M Noll et al. NATURE MEDICINE
- Limits to Personalized Cancer Medicine
- (2016) Ian F. Tannock et al. NEW ENGLAND JOURNAL OF MEDICINE
- Uncertainty in the Era of Precision Medicine
- (2016) David J. Hunter NEW ENGLAND JOURNAL OF MEDICINE
- Development and clinical application of an integrative genomic approach to personalized cancer therapy
- (2016) Andrew V. Uzilov et al. Genome Medicine
- Changing paradigm of cancer therapy: precision medicine by next-generation sequencing
- (2016) Yuan Xue et al. Cancer Biology & Medicine
- Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis
- (2015) N. Gopalakrishna Iyer et al. CANCER
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
- (2015) Marc van de Wetering et al. CELL
- The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
- (2015) Amber Johnson et al. DRUG DISCOVERY TODAY
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- SpDamID: Marking DNA Bound by Protein Complexes Identifies Notch-Dimer Responsive Enhancers
- (2015) Matthew R. Hass et al. MOLECULAR CELL
- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- An eleven gene molecular signature for extra-capsular spread in oral squamous cell carcinoma serves as a prognosticator of outcome in patients without nodal metastases
- (2015) Weining Wang et al. ORAL ONCOLOGY
- Personalized genomic analyses for cancer mutation discovery and interpretation
- (2015) Siân Jones et al. Science Translational Medicine
- Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance
- (2015) Andre Luiz Vettore et al. Genome Medicine
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Lessons from patient-derived xenografts for better in vitro modeling of human cancer
- (2014) Stephen Yiu Chuen Choi et al. ADVANCED DRUG DELIVERY REVIEWS
- Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
- (2014) F. Ricci et al. CANCER RESEARCH
- Patient-derived tumour xenografts as models for breast cancer drug development
- (2014) Elisabetta Marangoni et al. CURRENT OPINION IN ONCOLOGY
- YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer
- (2014) Fredrik Jerhammar et al. ORAL ONCOLOGY
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Clinical Approval Success Rates for Investigational Cancer Drugs
- (2013) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genomics-Driven Oncology: Framework for an Emerging Paradigm
- (2013) Levi A. Garraway JOURNAL OF CLINICAL ONCOLOGY
- Uniform, optimal signal processing of mapped deep-sequencing data
- (2013) Vibhor Kumar et al. NATURE BIOTECHNOLOGY
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Phase II and Phase III attrition rates 2011–2012
- (2013) John Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Sepantronium Bromide (YM155) induces disruption of the ILF3/p54nrb complex, which is required for survivin expression
- (2012) Tomohiro Yamauchi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
- (2012) Joseph Rosenbluh et al. CELL
- Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
- (2012) Naoto Nakamura et al. MOLECULAR & CELLULAR PROTEOMICS
- LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets
- (2012) Andreas Wilm et al. NUCLEIC ACIDS RESEARCH
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor
- (2010) William McLaren et al. BIOINFORMATICS
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- The Sequence Alignment/Map format and SAMtools
- (2009) H. Li et al. BIOINFORMATICS
- Circos: An information aesthetic for comparative genomics
- (2009) M. Krzywinski et al. GENOME RESEARCH
- Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling
- (2008) M. Ota et al. DEVELOPMENT
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started